Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Our Science
  • Our Pipeline
  • Patients & Families
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

PRESS RELEASES

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

PRESS RELEASES

Press Releases
Date Title
Sep 13, 2018 Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Aug 29, 2018 Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Aug 7, 2018 Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Aug 1, 2018 Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
May 29, 2018 Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
May 22, 2018 Ardelyx Announces Pricing of Public Offering of Common Stock
May 21, 2018 Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
May 21, 2018 Ardelyx Announces Proposed Public Offering of Common Stock
May 8, 2018 Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
Mar 19, 2018 Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Next page next ›
  • Last page last »
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2021 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS